XASX
4DX
Market cap1.68bUSD
Jul 10, Last price
3.96AUD
1D
-2.46%
1Q
-41.76%
IPO
915.38%
Name
4DMedical Ltd
Chart & Performance
P/E
—
P/S
404.34
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-4.10%
Rev. gr., 5y
36.56%
Revenues
6m
+55.91%
Net income
-30m
L-16.42%
CFO
-34m
L+11.69%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
4DMedical Limited operates as a medical technology firm with operations spanning both Australia and the United States. A core aspect of its business involves the commercialization of XV Technology, an advanced four-dimensional system for lung imaging. The company's offerings further extend to a software-as-a-service (SaaS) delivery model, alongside its proprietary XV lung ventilation analysis software. Additional products include Permetium, a preclinical imaging system designed to quantify localized changes in pulmonary function, and the AccuVent 200, a ventilator specifically tailored for small animals. Established in 2012, 4DMedical Limited is headquartered in Carlton, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||